Idroquark

Hydrochlorothiazide and Ramipril, the active ingredients in Idroquark, are a thiazide diuretic and an ACE inhibitor presented as an oral tablet for adult use. They treat hypertension and are used as adjunct therapy in patients with heart failure.

GNH USA supplies Idroquark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and our supply chain ensures timely delivery and supports clinical programs across multiple regions.

Idroquark is indicated for conditions within the cardiovascular disease spectrum where blood pressure control is required.

Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. Heart failure: used as adjunct therapy to decrease preload and afterload, aiding symptom control. Diabetic nephropathy: helps manage hypertension and may slow progression of renal impairment.

Idroquark may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urinary frequency - Electrolyte disturbances such as low potassium or sodium - Cough - Mild fatigue

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension leading to fainting - Acute renal failure or marked rise in serum creatinine - Hyperkalemia (dangerously high potassium levels) - Blood dyscrasias such as agranulocytosis

Before initiating Idroquark, clinicians should consider several safety measures.

Monitor blood pressure: regular checks to avoid excessive hypotension. Assess renal function: periodic serum creatinine and eGFR measurements. Check electrolytes: especially potassium and sodium levels. Avoid use in pregnancy: category D, potential fetal harm. Use caution in elderly: increased sensitivity to blood‑pressure changes. Store at room temperature: keep in the original pack, protect from moisture.

Idroquark can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - Aliskiren in diabetic patients: increased renal adverse events. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and impair renal function. - Other antihypertensives: additive hypotensive effect. - Corticosteroids: may increase urinary potassium loss.